Clinical features and prognosis of 33 patients with angioimmunoblastic T-cell lymphoma

SUN Hui; XUE Kai

doi:10.3969/j.issn.1002-266X.2015.19.004

Abstract：Objective To analyze the clinical characteristics and prognosis of patients with angioimmunoblastic T-cell lymphoma ( AITL) .Methods A retrospective analysis of 33 patients with AITL was performed in terms of basic clinical fea-tures, the therapeutic effect and prognostic factors.Results The median age of 33 patients was 61 years old, and 84.8%of them were male, 3 patients presented with poor performance status (ECOG score≥2), 27 cases had advanced stage (stageⅢ/Ⅳaccording to Ann Arbor classification), and 7 cases had elevated lactate dehydrogenase (LDH).Extranodal involve-ments included liver involvement (9.1%), spleen involvement (18.2%) and bone marrow involvement (9.1%).Fourteen patients presented with B symptom.Twenty four patients received CHOP regimen ( cyclophosphamide, doxorubicin, vincris-tine and prednisolone) as first-line chemotherapy.The 2-year overall survival ( OS) rate was 81.3% (95%CI: 0.734-0.892).The 2-year event-free survival (EFS) rate was 49.7%(95%CI:0.402-0.592).The elevated LDH, elevated white blood cell count and B symptom could affect 2-year OS rate (all P<0.05).ECOG score≥2, B symptom, skin rashes and a-nemia could affect 2-year EFS rate (all P<0.05).No statistical difference was found in 2-year OS rate between patients treated with non-CHOP and those with CHOP regimen.Multivariate analysis showed that ECOG score≥2 (P=0.023) was an independent adverse factor for worse EFS.B symptom (P=0.024) and the increased LDH level (P=0.034) were inde-pendent adverse factors for worse OS.Conclusions AITL usually occurs in elder men and presents with B symptom, skin ra-shes, eosinophilia, effusion and extranodal involvement.On onset of AITL, those with increased LDH and B symptom have a poor prognosis.Non-CHOP regimen in first-line chemotherapy is not superior to CHOP regimen.